Court Opinion

ID: 6221900
Source: CourtListenerOpinion
Date Created: 2022-02-15 18:01:29.154949+00
Date Added: 2024-06-11T08:57:23.431099
License: Public Domain

In the United States Court of Federal Claims
                                                  No. 14-820
                                          (Filed: 15 February 2022 *)

***************************************
MICHAEL MAGER, as parent of           *
MS. VICTORIA MAGER                    *
                                      *
                  Petitioner,         *                        Vaccine Act; Off-Table Case;
                                      *                        Autoimmune Epilepsy; Actual Causation;
v.                                    *                        Sudden Unexpected Death in Epilepsy
                                      *                        (“SUDEP”); Competing Diagnoses;
SECRETARY OF HEALTH AND HUMAN *                                Human Papilloma Virus Vaccine (“HPV”).
SERVICES                              *
                                      *
                  Respondent.         *
                                      *
***************************************

      Renee J. Gentry, Vaccine Injury Clinic, George Washington University Law School, of
Washington, DC, for petitioner.

        Zoe Wade, with whom were Laurie Wiesner, Trial Attorney, Heather L. Pearlman,
Deputy Director, C. Salvatore D’Alessio, Acting Director, Brian M. Boynton, Acting Assistant
Attorney General, Torts Branch, Civil Division, U.S. Department of Justice, of Washington, DC,
for respondent.

                                             OPINION AND ORDER

HOLTE, Judge.

        This case involves the tragic death of a child and the government’s system for
compensating vaccine-injured children—and by extension, their families. Congress designed the
Vaccine Act as part of “the Nation’s efforts to protect its children by preventing disease.” Cloer
v. Sec’y of Health & Hum. Servs., 654 F.3d 1322, 1325 (Fed. Cir. 2011) (quoting H.R. Rep. No.
99-908, at 4 (1986)). “[W]hile most of the Nation’s children enjoy greater benefit from
immunization programs, a small but significant number have been gravely injured.” Id. “[F]or
the relatively few who are injured by vaccines,” Congress noted the “opportunities for redress
and restitution [were] limited, time-consuming, expensive, and often unanswered.” Id. In
response, “Congress created the Vaccine Program” to “compensate injured persons quickly and
fairly” for injuries “either presumed or proven to be causally connected to vaccines.” Id. This

*
 This opinion was initially filed under seal pursuant to Vaccine Rule 18(b) of the Rules of the Court of Federal
Claims. The Court provided the parties 14 days to submit proposed redactions, if any, before the opinion was
released for publication. Neither party proposed redactions. This opinion is now reissued for publication in its
original form.
Program “exempt[s] petitioners from the burden of proving causation” by removing “the tort
requirements of demonstrating that a manufacturer was negligent or that a vaccine was
defective.” Id. In short, the Act “assure[s] parents that when their children are the victims of an
appropriate and rational national policy, a compassionate [g]overnment will assist them in their
hour of need.” Boatmon v. Sec’y of Health & Hum. Servs., 941 F.3d 1351, 1364 (Fed. Cir. 2019)
(Newman, J., dissenting on unrelated grounds) (quoting Sen. Edward Kennedy, S. Comm. on
Labor & Human Res.).

        Michael Mager seeks compensation for his daughter’s seizure disorder and death, which
he alleges are the result of her being vaccinated for the human papilloma virus. Ms. Mager’s
first documented seizure occurred shortly after receiving the first HPV vaccine dose. The
seizures subsided for several years until she received a second dose of the HPV vaccine, at which
point her seizures returned and became more regular—ultimately resulting in her death. The
Special Master denied Mr. Mager’s petition because, according to the Special Master, there was
insufficient evidence to support a diagnosis of Autoimmune Epilepsy, which the Special Master
considered to be necessary for Mr. Mager’s argument to succeed. Mr. Mager moves the Court
for review of the Special Master’s decision denying his petition. According to Mr. Mager, the
Special Master abused his discretion by mischaracterizing Mr. Mager’s medical theory of his
daughter’s injury, failing to adhere to precedential case law when considering whether the
vaccine caused her injury, and failing to consider the entirety of the evidence. For the following
reasons, the Court grants petitioner’s motion, vacates the Special Master’s order, and remands
this case to the Special Master for further proceedings consistent with this opinion.

I. Petitioner’s Medical History and the Vaccination

        As the basic facts have not changed significantly, the Court’s recitation of the
background facts draws from the Special Master’s Decision Denying Compensation, ECF
No. 189. Ms. Mager’s health history was relatively normal before receiving the vaccination for
the human papilloma virus (“HPV”). 1 Ms. Mager received the vaccine on 2 October 2007. Pet.
at 1, ECF No. 1. Six weeks later, Ms. Mager suffered a seizure and was taken to a nearby
emergency room. Pet’r’s Ex. 11 at 28, ECF No. 9-4. The admission notes from that visit state
she experienced a seizure followed by a second seizure approximately four minutes later. Id.
Her head CT scan, urine toxicology screen, and chest x-ray were all normal. Id. at 3–4, 13. An
electroencephalogram (“EEG”) “indicate[d] focal sites of cerebral hyperexcitability which can be
associated with partial seizures/epilepsy.” Id. at 17. Ms. Mager was prescribed Depakote, an
anti-seizure medication, and discharged on 15 November 2007. Id. at 38.

       In a follow-up visit on 12 December 2007, Ms. Mager’s physician, Dr. Shafrir, noted that
her parents recalled that “for a while [after her initial seizure], [Ms. Mager] was waking up with

1
 While the government argues Ms. Mager’s seizures began before she was vaccinated for the human papilloma
virus, the parties agree the onset of her seizures is ambiguous and the Special Master made no finding concerning
when the seizures began. Mot. for Review Oral Arg. Tr. (“Tr.”) at 20:21–22:14, ECF No. 197 (“COURT: Did the
Special Master make any findings about seizures occurring before the HPV vaccine? [GOVERNMENT:] He did
not. THE COURT: [Petitioner], any follow-up on that? [PETITIONER]: . . . I agree . . . .”). The only exception to
Ms. Mager’s normal health was, at twelve-years-old, she required speech therapy, demonstrated “poor school
performance,” “decreased attention” at school, and suffered from enuresis, or bed wetting. Pet’r’s Ex. 18 at 5, ECF
No. 22-2.

                                                       -2-
big cuts in her tongue at least twice and also complaining of soreness after waking up and it is
possible that these might have been seizures.” Pet’r’s Ex. 11 at 75. Ms. Mager’s stepmother
also reported Ms. Mager’s enuresis was resolved after she began taking her antiseizure
medication, Depakote. Id. Dr. Shafrir noted the EEG indicated an impression of “focal onset
epilepsy” and “some frontal lobe dysfunction,” and he recommended neuropsychological testing.
Id. at 77.

        Approximately two months later, Ms. Mager saw another pediatric neurologist, Dr.
Koehn, who ordered another EEG—the results of which were normal. Pet’r’s Ex. 6 at 22, ECF
No. 8-7. Dr. Koehn noted, referring to the original abnormal EEG, that “[t]he first EEG pattern
could represent a fragment/a more lateralized pattern of an underlying generalized discharge or it
could in fact be a focal discharge. Therefore, leaving the possibility open for this to have been a
primary or secondarily generalized seizure.” Id. at 20. Although the medication appeared to
control her seizure activity, Ms. Mager’s father and stepmother noted undesirable side effects of
the medication and requested she be weaned off Depakote. Id. at 24. Accordingly, Dr. Koehn
agreed to gradually wean Ms. Mager from Depakote and referred her for neuropsychological
testing. Id. at 28; see also Pet. at 1.

        Shortly after seeing Dr. Koehn, Ms. Mager saw another physician, Dr. Waltonen, for
neuropsychological testing. Pet’r’s Ex. 6 at 6. Dr. Waltonen observed she had “a history of
some type of learning difficulty at least in the speech and language area.” Id. He also noted Ms.
Mager had a family history of epilepsy and seizures on her maternal side. Id. at 2. He noted
reports of “increasing problems with doing well in school” and Ms. Mager’s teachers indicated
she had “problems following directions.” Id. at 1, 4. Ultimately, Dr. Waltonen concluded that
“[o]verall, her examination does not reveal evidence of significant cognitive impairment with the
exception of these very focal language findings.” Id. at 6.

        From April 2008 to October 2012, Ms. Mager did not experience any seizure activity and
appeared to function normally. Her school records did not indicate any abnormalities. See
Pet’r’s Ex. 83, ECF No. 144-3. The results of sport physicals she received in August 2009 and
March 2012 were normal. Pet’r’s Ex. 10 at 15–17, ECF No. 9-3; Pet’r’s Ex. 14 at 1–2, ECF
No. 12-2. During a physical exam in January 2012, she reported she had not experienced seizure
activity for four years. Pet’r’s Ex. 10 at 18. Ms. Mager received her second HPV vaccination on
11 September 2012. Pet’r’s Ex. 4 at 1, ECF No. 8-5. The following month, on 10 October 2012,
she suffered a seizure and was taken to the emergency department of a nearby medical center.
Pet’r’s Ex. 7 at 9, ECF No. 8-8. Her evaluation, which included an EKG, was normal. Id. at 13–
14. She was diagnosed with a “[p]robable seizure” and discharged. Id. at 14.

       In a visit with her primary care doctor the next month, she reported two additional
seizures occurring on 19 October 2012 and 7 November 2012 after her ER visit. Pet’r’s Ex. 9 at
39, ECF No. 9-2. Her doctor prescribed an antiseizure medication, Depakote, and referred her to
a neurologist. Id.

        Neurologist Dr. Edgar saw Ms. Mager a couple months later in January 2013. Pet’r’s Ex.
9 at 24–25. According to Dr. Edgar’s note, “[t]he EEG is normal during wakefulness. During
sleep there is activation of infrequent potentially epileptiform activity over the left frontal and

                                               -3-
bioccipital head regions, consistent with the patient’s history of generalized seizures.” Id. at 25.
Dr. Edgar believed Ms. Mager suffered from primary generalized seizure disorder, and he noted
the “age of onset at approximately 11 years of age suggests the possibility of juvenile myoclonic
epilepsy, although no myoclonic seizures are reported.” Id. at 31. He recommended Depakote,
but due to Ms. Mager’s objections, he directed her to begin weaning off Depakote and prescribed
Keppra, an alternative antiseizure medication, instead. Id. at 8.

        Dr. Edgar observed during a follow-up appointment in July 2013 that Ms. Mager’s
compliance with her Keppra prescription was “less than ideal”; she had a sub-therapeutic level of
the medication in her blood according to a test on 30 May 2013. Pet’r’s Ex. 9 at 3. Ms. Mager
wanted to stop using Keppra, but Dr. Edgar persuaded her to remain on the drug given her
history of seizures. Id. at 4. Due to her age at the onset of her seizure condition, Dr. Edgar again
noted “probable juvenile myoclonic epilepsy.” Id.

        Months later, on 11 January 2014, Ms. Mager was found unresponsive at a friend’s house
and was rushed to the emergency department of a nearby hospital where she was pronounced
dead upon arrival. Pet’r’s Ex. 8 at 2, ECF No. 8-9. The local police department reported a
witness statement that Ms. Mager had been “missing a lot of doses of her medication,” and her
father reported that “she was having seizures more frequently.” Pet’r’s Ex. 13 at 2, ECF No. 9-6.

        According to an autopsy, Ms. Mager suffered pulmonary edema and brain changes
consistent with a seizure disorder. Pet’r’s Ex. 16 at 10, ECF No. 18-2. There was subpial gliosis
in sections of her brain. Id. at 16. A toxicology screen showed therapeutic levels of Keppra in
her blood. Pet’r’s Ex. 13 at 11. The cause of Ms. Mager’s death was “seizure disorder”
according to her death certificate. Pet’r’s Ex. 1 at 1, ECF No. 8-2.

        The parties agree Ms. Mager suffered from a seizure disorder that caused her death, Tr.
6:14–16, but they dispute the underlying diagnosis. Pet’r’s Prehr’g Br. at 9, ECF No. 168
(“Petitioner contends [Ms. Mager] suffered from autoimmune epilepsy that resulted in sudden
unexpected death with epilepsy or SUDEP.”); Gov’t’s Prehr’g Br. at 1, ECF No. 180 (“the
evidence supports that Ms. Mager most likely suffered from juvenile myoclonic epilepsy”).

II. The Petition and Procedural History Before the Special Master

        Petitioner filed his petition alleging the HPV vaccination caused Ms. Mager to suffer a
seizure disorder leading to her death on 11 January 2014. Pet. at 2. All relevant medical records
were submitted, and the record was complete on 17 February 2015. See Statement of
Completion, ECF No. 23. A couple months later, the Secretary filed his report contesting
causation and arguing Ms. Mager’s seizure disorder preexisted her vaccination. See Resp’t’s
Rule 4(c) Report, ECF No. 25. After a change in counsel and experts, and multiple extensions of
time, the parties submitted their experts’ reports. See Pet’r’s Ex. 55, ECF 116-1; Gov’t’s Ex. Z,
ECF No. 128-1; Gov’t’s Ex. AA, ECF No. 129-1; Pet’r’s Ex. 85, ECF No. 165-2; Gov’t’s
Ex. CC, ECF No. 182-1; Gov’t’s Ex. BB, ECF No. 183-1. Petitioner’s expert, Dr. Shafrir,
asserted Ms. Mager’s epilepsy was autoimmune in nature based, in part, on autoimmune
reactions to the vaccine. Pet’r’s Ex. 55 at 18. Respondent’s experts, Dr. Kohrman and

                                                -4-
Dr. Fujinami, however, both stated Ms. Mager suffered from juvenile myoclonic epilepsy
(“JME”). Gov’t’s Ex. Y at 7, ECF No. 95-3; Gov’t’s Ex. CC at 1–2.

        The Special Master ordered the parties to submit briefs in advance of potential
adjudication on 20 November 2019, ECF No. 142. After multiple extensions, Mr. Mager filed a
supplemental expert report from Dr. Shafrir on 25 July 2020, ECF No. 167, and his brief on 27
July 2020, ECF No. 168. The Secretary, again after multiple extensions, filed his supplemental
expert reports from Dr. Fujinami and Dr. Kohrman, as well as his brief, on 10 February 2021,
ECF Nos. 180–83. Mr. Mager filed his reply brief on 26 March 2021, ECF No. 186.

        In the interim period between the parties’ briefing and the Special Master’s decision, a
significant colloquy between the Special Master and petitioner took place. The Special Master
issued an order in June asking petitioner to “identify the source of the diagnostic criteria for
autoimmune epilepsy listed in his [prehearing] brief.” Order at 1, ECF No. 187. Petitioner
responded accordingly the next day but noted “[t]he criteria are discussed in that section solely to
demonstrate that autoimmune epilepsy can present as milder epilepsy.” Status Report Re Order
of June 16, 2021 (“Pl.’s Resp. to Special Master’s 16 June 2021 Questions”) at 1, ECF No. 188
(emphasis added).

       The Special Master then issued his decision denying compensation the following month
on 29 July 2021. See Decision Den. Compensation, ECF No. 189. In his decision, the Special
Master denied petitioner’s claim on the basis that there was insufficient evidence to support a
diagnosis of Autoimmune Epilepsy. Id. at 16–17.

       A. Expert Reports

        In weighing the evidentiary value of the parties’ experts’ opinions, the Special Master
determined petitioner’s expert, Dr. Shafrir, and the government’s expert, Dr. Kohrman, both
“have ample experience and expertise in pediatric neurology[;] Dr. Kohrman has a notable
special expertise in epilepsy.” Decision Den. Compensation at 9. The Special Master noted “Dr.
Shafrir’s certifications and topics of focus in his publications are certainly relevant and helpful to
this case,” but determined “Dr. Kohrman’s specialty in epilepsy—particularly his board
certification with a subspecialty in epilepsy and focus on pediatric epilepsy—makes him
particularly qualified to opine on a case in which potential diagnoses of autoimmune epilepsy or
juvenile myoclonic epilepsy are at play.” Id.

        Dr. Shafrir, believes Ms. Mager’s seizures and death were caused by a neurological
reaction to the HPV vaccination. He explains:

       [B]ecause of some unknown and a very rare genetic susceptibility, [Ms. Mager] had
       an abnormal immune reaction to the HPV vaccination which produced brain
       inflammation in autoimmune epilepsy. The reactivation of the autoimmune and
       inflammatory mechanism with the second vaccination, produced recurrence of her
       epilepsy with more frequent seizures. The mechanism is likely based on molecular
       mimicry which could be supplemented by activation of the innate immune
       system . . . .

                                                -5-
Pet’r’s Ex. 55 at 17. The HPV vaccine, according to Dr. Shafrir, is a uniquely potent stimulator
of the immune system. Id. at 19 (“In contrast to many other vaccines, the level of antibodies
produced by [sic] HPV vaccine is more than 10 to 100[-]fold higher than the level of antibodies
produced by the natural infection.”). The medical literature he cites identifies examples of brain
autoimmunity related to the HPV vaccination and proteins. Id. “[A]wareness of autoimmune
epilepsy has dramatically increased in the last several years,” says Dr. Shafrir, to the extent that
“[c]hecking autoantibodies in appropriate cases of intractable epilepsy has become the standard
of care.” Id. at 18–19.

        Here, there is strong evidence of an autoimmune inflammatory reaction, according to Dr.
Shafrir, because Ms. Mager’s autopsy report found evidence of gliosis which suggests
inflammation of the brain. Id. at 20. He further reasons the occurrence and recurrence of
Ms. Mager’s seizures in correlation with the HPV vaccine demonstrates it caused her seizures
and death. He explains:

       The relationship between vaccinations and her seizures is based on a “rechallenge”
       test and has been performed here with another episode of seizure occurring after
       her second HPV vaccination but not after [other vaccinations] given before the sec-
       ond HPV vaccination. One has to understand that in clinical situations, such a
       rechallenge for any treatment, medication or immunization would suffice to
       confirm a causal relationship.

Pet’r’s Ex. 55 at 17, ECF No. 116-1. Dr. Shafrir emphasized the importance of the relationship
between the vaccination and Ms. Mager’s seizures in a supplemental report:

       [T]he near identical sequence of events following each of the HPV vaccinations
       qualify as “certain” in the causality assessment of suspected adverse drug reactions,
       according to the existing criteria described in [the cited medical literature] in my
       first report. What is crucial here is the fact that Ms. Mager could stop antiepileptic
       medication and remained seizure free throughout the entire period of more than
       three years before the second vaccination. After the second vaccination in the
       recurrence of the seizures, the seizures became more frequent. In part, this is a
       result of her lack of easy access to neurological care, insurance issues which may
       have affected her ability to get her medications, and general lack of compliance.
       According to a witness after her death, she reported that she has seizures every
       week. This suggests that the immune reaction to the HPV vaccine, which produced
       the seizures, was more severe and more prolonged after the second vaccination
       probably because of the presence of immunological memory.

Pet’r’s Ex. 85 at 1 (citations omitted). This relationship between the vaccination and the
seizures, Dr. Shafrir reasoned, “is another strong support . . . for the causal relationship between
the [HPV] vaccination and [Ms. Mager’s] seizure disorder and unexpected death.” Pet’r’s Ex. 55
at 20.

                                                -6-
        The government submitted reports from two experts, Dr. Kohrman and Dr. Fujinami,
both of whom dispute Dr. Shafrir’s theory of autoimmune epilepsy caused by the HPV vaccine.
See Gov’t’s Exs. Z, AA, BB, CC. According to Dr. Kohrman, evidence weighing against a
diagnosis of autoimmune epilepsy includes: (1) treating physicians diagnosed Ms. Mager with
primary generalized epilepsy; (2) evidence Ms. Mager’s seizures predated the HPV vaccine; (3)
absence of history of focal clinical seizures in the medical record; (4) absence of evidence
indicating an autoimmune process in the autopsy report; and (5) absence of test results indicating
presence of antineuronal antibodies. Gov’t’s Ex. BB at 12.

      Regarding Dr. Shafrir’s emphasis on the correlation between the HPV vaccine and
Ms. Mager’s seizures, Dr. Kohrman commented:

       Given the diagnosis of a primary generalized epilepsy, that was never adequately
       treated [due] to family request and behavior, and the lack of patient taking [sic]
       meds[,] [h]er history and clinical course cannot be considered a
       challenge[-]rechallenge. It was never documented medically that she was
       seizure[-]free prior to [sic] second vaccination.         The[re] is not [sic]
       contemporaneous medical record of her seizures noted between July 2008 and her
       second vaccination. Her seizures were primarily nocturnal and she did not always
       recognize these according to her [f]ather.

Id. (citation omitted). Ms. Mager’s diagnosis, according to Dr. Kohrman, was most likely
juvenile myoclonic epilepsy (“JME”). Id. at 14. Dr. Kohrman explains:

       JME is an idiopathic generalized epilepsy syndrome characterized by myoclonic
       seizures, generalized tonic-clonic seizures, and absence seizures. It is extremely
       common, accounting for [twenty-six percent] of idiopathic generalized epilepsies
       . . . and [ten percent] of all epilepsies . . . . [T]he average age of onset is 15.1 years
       ([seven to twenty-eight] years) with a slight female predominance. In the classic
       syndrome of JME, myoclonic seizures may precede the first generalized tonic-
       clonic seizure . . . by [six to twelve] months, although [generalized tonic-clonic
       seizures] occur as the first seizure type in approximately one-third of patients.
       Some have proposed specific subgroups of JME separating those patients who
       present with typical childhood absence or juvenile absence seizures, although this
       is much less common than the classical presentation of JME, accounting for only
       [ten percent] of cases . . . . Photosensitivity is relatively common, occurring in
       approximately [thirty percent] of patients.

Id. at 2. Dr. Kohrman reviewed Ms. Mager’s medical history and determined her diagnosis was
most likely JME. Id. at 15. He pointed to her treating physician’s comment that her epilepsy
was likely JME due to her age. Id. at 2, 14 (citing Pet’r’s Ex. 10 at 23). He believed her medical
history also supported a diagnosis of JME; specifically, that her seizures appeared to be
controlled with antiseizure medication and other evidence such as her history of tongue-biting
and enuresis (which he considered to be evidence of nocturnal seizures), her family history of
epilepsy, and her history of speech and learning problems. Gov’t’s Ex. BB at 2, 14. He also
explained her seizures were described as generalized tonic-clonic seizures and her EEGs showed

                                                 -7-
generalized epileptiform activity, both of which are consistent with a diagnosis of JME. Id.
at 14.

        Dr. Kohrman did not believe Ms. Mager suffered from autoimmune epilepsy. Id. at 12.
He repeated her treating physician’s diagnosis of primary generalized epilepsy and noted JME
falls on a spectrum of primary or idiopathic generalized epilepsies. Id. at 2, 12. He also believed
her seizure disorder predated her HPV vaccination and observed there was an absence of
evidence of antineuronal antibodies. Id. at 12. Regarding Dr. Shafrir’s suggestion that the
autopsy revealed gliosis which indicated inflammation in the brain, Dr. Kohrman explained
“subpial gliosis is a regular finding in juvenile myoclonic epilepsy. The pathologist at necropsy
concluded this was a typical finding in epilepsy and [Ms. Mager had] generalized epilepsy . . . .”
Id. at 15. Dr. Fujinami also believed Ms. Mager suffered from JME and observed that
Ms. Mager’s seizures were not resistant to antiseizure medication, as would be the case if her
seizures were caused by autoimmune epilepsy. Gov’t’s Ex. CC at 1.

         B. The Special Master’s Decision Denying Compensation

         The Special Master’s analysis in terms of the diagnostic criteria for autoimmune epilepsy
is clear, thorough, and well-reasoned. The Special Master began his analysis by weighing the
relative qualifications of the experts, specifically Dr. Shafrir and Dr. Kohrman. Decision Den.
Compensation at 9. The Special Master considered both experts to be well qualified but found
“Dr. Kohrman’s specialty in epilepsy—particularly his board certification with a subspecialty in
epilepsy and focus on pediatric epilepsy—makes him particularly qualified to opine on a case in
which potential diagnoses of autoimmune epilepsy or juvenile myoclonic epilepsy are at play.”
Id.

        Next, the Special Master carried out a thorough analysis applying the diagnostic criteria
petitioner identified for autoimmune epilepsy to the facts of this case. He explained this was
necessary “because [petitioner’s] theory of causation relies on an autoimmune disease causing
neuroinflammation.” 2 Id. at 4. The three diagnostic criteria the Special Master considered were:
“(1) ‘demonstration of autoantibodies against neuronal components in the patient’s blood’; (2) in
most patients, seizures that ‘may not respond to regular antiepileptic medications but respond to
immunomodulatory treatment’; and (3) ‘occurring in relation to an autoimmune disease or
autoimmune encephalitis.’” Id. at 10 (citing Pet’r’s Prehr’g Br. at 9–10, ECF No. 168).

        Looking at the first criterion, the presence of autoantibodies against neuronal components
in the patient’s blood, the Special Master found there was “no affirmative evidence on this
point.” Id. at 10. This is a key criterion because the presence of neuronal antibodies in the blood
is conclusive evidence of an autoimmune reaction. Id. Unfortunately, an antibody test was not
performed in this case. Decision Den. Compensation at 10. The Special Master noted

2
  Petitioner admits Ms. Mager’s condition does not fit the diagnostic criteria for autoimmune epilepsy. Tr. at
34:7–20. When asked why petitioner included the diagnostic criteria for autoimmune epilepsy, counsel for
petitioner explained: “I do not believe that she meets the diagnostic criteria. Neither does Dr. Shafrir, and he stated
that for the most severe case. . . . [O]ften in clinical settings, you’re going to get a diagnosis that doesn’t . . . meet
all the diagnostic criteria. We’ve not alleged that she meets that diagnostic criteria in this case. We are alleging . . .
that she meets the general clinical definitions based on the etiology of her epilepsy.” Tr. at 34:11–20.

                                                          -8-
petitioner’s “potentially valid reasons” why Ms. Mager’s treating physicians may not have
thought to perform tests for autoimmune antibodies—particularly that “autoimmune epilepsy is a
relatively ‘emerging field.’” Id. (citing Pet’r’s Reply to Resp’t’s Prehr’g Mem. at 18, ECF
No. 186). The Special Master reasoned, however, “a lack of evidence on this point does not help
Mr. Mager’s case.” Id. “While this fact is not dispositive as to the determination of whether
[Ms. Mager] had autoimmune epilepsy, and does not rule out autoimmune epilepsy,” the Special
Master reasoned, “a lack of testing also does not provide any affirmative evidence supporting an
autoimmune epilepsy diagnosis.” Id.

        The Special Master considered the autopsy report’s finding of gliosis and whether it was
an indicator of an inflammatory process, as Dr. Shafrir argued, but concluded the evidence was
tenuous because the experts dispute its significance as it pertains to evidence of autoimmunity.
Id. at 11. The Special Master cited Dr. Fujinami, who argued gliosis is a “common finding in
epilepsy and represents the result of a neuronal injury and cell death . . . and not an acute or
chronic inflammatory process related to vaccination,” and Dr. Kohrman who said gliosis is a
“regular finding in juvenile myoclonic epilepsy.” Id. at 10–11 (citing Gov’t’s Ex. Y at 7;
Gov’t’s Ex. BB at 15). Besides, the Special Master reasoned, “[i]t also does not provide
evidence of autoimmune antibodies in [Ms. Mager’s] blood, which is the actual relevant criterion
in terms of testing for a diagnosis of autoimmune epilepsy.” Decision Den. Compensation at 11.
Thus, the Special Master concluded there was an absence of evidence indicating the presence of
autoantibodies, the first criterion for a diagnosis of autoimmune epilepsy. Id. at 10.

        Regarding the second criterion, the Special Master found there was insufficient evidence
to conclude Ms. Mager’s seizures were resistant to antiseizure medication. Id. at 12. The
Special Master considered petitioner’s argument that at least two incidents demonstrated
Ms. Mager’s seizures were refractory: (1) Ms. Mager suffered a seizure the night she was
discharged from the hospital in November 2007 after she started taking Depakote, an antiseizure
medication; and (2) Ms. Mager had a therapeutic level of antiseizure medication, Keppra, in her
blood at the time of her death. Id. at 11. The Special Master was not persuaded either incident
was the result of resistance to antiseizure medication. Id. at 12. In the first instance, the Special
Master reasoned, Ms. Mager’s seizures and seizure-related activity (e.g., enuresis) appeared to be
controlled while she continued taking Depakote. Id. at 11–12. In the second, multiple sources of
evidence suggested Ms. Mager did not take her medication as prescribed in the period preceding
her death. Decision Den. Compensation at 12. In sum, the Special Master found the evidence in
favor of finding the petitioner satisfied the second criterion was unpersuasive.

        Turning to the third criterion, the Special Master carried out an extensive analysis as to
whether Ms. Mager suffered from autoimmune encephalitis. 3 Id. at 13. The Special Master
evaluated six clinical features of autoimmune encephalitis the petitioner identified. Id. (citing
Pet’r’s Reply to Resp’t’s Prehr’g Mem. at 11). Those six clinical features include:

3
  At oral argument, petitioner argued: “[W]e never alleged autoimmune encephalitis. We were, again, submitting
evidence showing that anything that can cause this severe a storm of autoimmune encephalitis can cause something
less than that.” Tr. at 29:22–30:1. In petitioner’s prehearing reply brief, however, “[p]etitioner contends [Ms.
Mager] suffered from autoimmune-triggered encephalitis, which caused her epilepsy and eventual SUDEP.” Pet’r’s
Reply to Resp’t’s Prehr’g Mem. at 10.

                                                     -9-
       (1) Focal seizures, particularly focal motor and focal dyscognitive, secondary
       generalized seizures; (2) seizure clusters, status epilepticus; (3) seizures and
       epilepsy of unknown cause; (4) refractory seizures; (5) associated features of
       encephalopathy, movement disorders, neuropsychiatric symptoms, cognitive or
       memory impairment; and (6) history of autoimmune diseases (personal or family).

Id. The Special Master found there was insufficient evidence to satisfy these criteria, except the
third (i.e., seizures of unknown cause). Id. at 15–16. The Special Master summed up:

       [T]he only diagnostic criterion that Mr. Mager has met his burden to show is that
       [Ms. Mager’s] seizures were of an unknown cause. It follows that Mr. Mager has
       then not met his burden in showing that [Ms. Mager] suffered from autoimmune
       encephalitis, as this is only one of six diagnostic criteria, and one that is relatively
       less weighty given that it by definition indicates a lack of information regarding
       [Ms. Mager’s] condition.

Id.

III. Petitioner’s Motion for Review and Respondent’s Arguments

       A. Petitioner’s Arguments

         Petitioner alleges “[t]he Special Master abused his discretion by mischaracterizing
[p]etitioner’s position with respect to diagnosis and ignoring significant points made by
[p]etitioner’s expert with respect to the diagnosis and causation, to such an extent as to deny
[p]etitioner his full and fair hearing.” Mot. for Review at 2, ECF No. 191. According to
petitioner, the Special Master commits two errors regarding Ms. Mager’s diagnosis: (1) he
conflates her diagnosis before death with her alleged injury; and (2) he focuses on the
autoimmune epilepsy portion of Dr. Shafrir’s proposed causation theory and fails to consider Dr.
Shafrir’s theory in its full context. Id. at 16. Petitioner argues he “is not hinging his case on a
diagnosis of autoimmune epilepsy, nor did he proffer the diagnostic criteria to support a
diagnosis of autoimmune epilepsy. Rather, [p]etitioner argue[s] that [Ms. Mager] experienced
[sudden unexpected death with epilepsy] as a result of her epilepsy which was, yes, likely to be
autoimmune in nature.” Id. at 17.

        Petitioner maintains his “predominant argument was that [Ms. Mager] experienced
challenge/rechallenge . . . . Rechallenge is not dependent on a finding that [Ms. Mager] suffered
from autoimmune epilepsy. It is dependent on [Ms. Mager] suffering an adverse event, in this
case seizures, after more than one administration of a particular vaccine, e.g.[,] the HPV
vaccination.” Id. While petitioner’s expert, Dr. Shafrir, testified Ms. Mager’s HPV vaccination
triggered autoimmune epilepsy in Ms. Mager, petitioner argues “the complexity of her diagnosis
cannot be stripped down to the three [diagnostic] criteria [for autoimmune epilepsy] as the
Special Master did in this case. Particularly, when [those] criteria [are] offered to demonstrate
that autoimmune epilepsy can present in a range of severity including the milder epilepsy from
which [Ms. Mager] suffered.” Id.

                                                - 10 -
        Petitioner argues the Special Master improperly failed to consider the entirety of
petitioner’s claim by limiting his analysis to the diagnostic criteria for autoimmune epilepsy
before dismissing the case. Id. at 18. According to petitioner, the Special Master’s reliance on
Lombardi v. Sec’y of Health & Hum. Servs., 656 F.3d 1343 (Fed. Cir. 2011), and Broekelschen v.
Sec’y of Health & Hum. Servs., 618 F.3d 1339 (Fed. Cir. 2010), is misplaced, and the Special
Master should have analyzed the case under Althen v. Sec’y of Health & Hum. Servs., 418 F.3d
1274 (Fed. Cir. 2005), and its progeny because Lombardi and Broekelschen are distinguishable.
Mot. for Review at 18.

        Plaintiff further argues the Special Master was obliged to consider the entire record
before disposing of the case due to his decision to not hold a hearing. Id. at 15. To support his
proposition that the procedural posture of a case affects the Special Master’s burden to consider
the evidence, petitioner cites Moriarty by Moriarty v. Sec’y of Health & Hum. Servs., 844 F.3d
1322, 1333 (Fed. Cir. 2016). Id. “In the instant matter,” petitioner argues, “the Special Master’s
refusal to conduct an evidentiary hearing . . . renders it particularly important that he review the
entire record . . . . If a Special Master may not, as a matter of law, decline to consider evidence
on the record only because it was not discussed at hearing [as was the case in Moriarty], it is
even more imperative that he consider all the evidence when he also declines to conduct a
hearing.” Id.

       B. Respondent’s Arguments

         Respondent argues petitioner affirmatively articulated a causation theory that hinges on
an autoimmune epilepsy diagnosis. Resp. to Mot. for Review at 10, ECF No. 193. Specifically,
respondent points to petitioner’s statements that his theory of causation is a “neurological
autoimmune process triggered by the HPV vaccine, causing autoimmune epilepsy[,]” and “the
initial HPV vaccine dose caused [Ms. Mager’s] epilepsy and the subsequent dose aggravated that
condition through a neurological autoimmune process causing autoimmune epilepsy.” Id.
(quoting Pet’r’s Prehr’g Br. 16, ECF No. 168). Respondent maintains “[i]t is thus plain that
petitioner’s case hinged on the argument that Ms. Mager developed autoimmune epilepsy.” Id.

       Respondent cites the Special Master’s decision which summarizes the experts’ opinion
on Ms. Mager’s diagnosis:

       Dr. Shafrir asserted a diagnosis of autoimmune epilepsy based, in part, on what he
       deemed neurological reactions to the vaccine that suggested underlying
       autoimmune encephalitis. Dr. Kohrman, however, maintained a diagnosis of
       juvenile myoclonic epilepsy (“JME”), based on his view that [Ms. Mager] suffered
       pre-vaccination seizure activity, non-focal (i.e. generalized) seizures, and a lack of
       evidence regarding an autoimmune process in [Ms. Mager’s] autopsy. Dr. Fujinami
       agreed with the JME diagnosis, highlighting that [Ms. Mager’s] seizures were not
       treatment resistant, as would be true of seizure activity involved in autoimmune
       epilepsy.

Id. at 11 (quoting Decision Den. Compensation at 3). Respondent further cites the Special
Master’s conclusion that “[t]he difference between autoimmune epilepsy and JME . . . affects the

                                               - 11 -
outcome of [petitioner’s] case because his theory of causation relies on an autoimmune disease
causing neuroinflammation.” Id. at 12 (quoting Decision Den. Compensation at 4).
“Accordingly,” respondent argues, “it was necessary and legally correct for the Special Master to
undertake a preliminary inquiry regarding whether petitioner met his burden in proving that Ms.
Mager suffered from autoimmune epilepsy.” Id.

        Respondent argues petitioner now disavows his allegation that Ms. Mager’s seizure was
caused by her autoimmune epilepsy. Resp. to Mot. for Review at 12. According to respondent,
“[i]f petitioner was not relying on a diagnosis of autoimmune epilepsy, or wanted the Special
Master to consider criteria from a different condition, he had plenty of chances to clarify his
position. As the Special Master points out, ‘[t]he parties have had ample opportunity to develop
their positions through submissions of evidence (primarily medical records) about [Ms. Mager],
lengthy and multiple expert reports, and thorough briefing.’” Id. at 12 (quoting Decision Den.
Compensation at 18).

        Regarding the Special Master’s decision to resolve the claim without an evidentiary
hearing, respondent argues “[t]he Vaccine Rules explicitly authorize a special master to make
findings of fact and decide a case on the basis of the written record without an evidentiary
hearing.” Id. at 14 (citing VRCFC 8(d); Dickerson v. Sec’y of Dep’t of Health & Hum. Servs., 35
Fed. Cl. 593, 598 (1996); Plummer v. Sec’y of Dep’t of Health & Hum. Servs., 24 Cl. Ct. 304,
307 (1991)). Respondent cites 42 U.S.C. § 300aa-12(d)(3)B(v) (2018), which provides a special
master “may conduct such hearings as may be reasonable and necessary,” (emphasis added), for
supporting its argument the decision whether to hold a hearing is within the Special Master’s
discretion. Id.

       According to respondent, the Special Master afforded petitioner a full and fair hearing:

       It is evident from the case record that the Special Master carefully evaluated all of
       the evidence and decided the case on the merits. The Special Master found that
       petitioner’s “claim fails for reasons that a hearing could not cure given the paucity
       of evidence establishing a diagnosis of autoimmune epilepsy, which is essential for
       the remainder of [petitioner’s] claim to proceed.” The Special Master observed,
       “[petitioner] has had a full and fair opportunity to present his case. Thus, a
       disposition on the papers is appropriate.”

Id. at 15 (quoting Decision Den. Compensation at 18). Respondent further argues the Special
Master’s decision to forgo an evidentiary hearing conserved judicial resources and provided a
simplified process consistent with the legislative intent of the Vaccine Act. Id.

IV. Legal standards

       A. The Court’s Standard of Review of a Special Master’s Decision

        The Vaccine Act provides this Court jurisdiction to review a Special Master’s decision
upon timely motion of either party. See 42 U.S.C. § 300aa-12(e)(1)–(2). In reviewing the record
of the proceedings before the Special Master, the Court may: (1) “uphold the findings of fact

                                              - 12 -
and conclusions of law of the special master and sustain the special master’s decision”; (2) “set
aside any findings of fact or conclusion of law of the special master found to be arbitrary,
capricious, an abuse of discretion, or otherwise not in accordance with law and issue its own
findings of fact and conclusions of law”; or (3) “remand the petition to the special master for
further action in accordance with the court’s direction.” § 300aa-12(e)(2). “Fact findings are
reviewed . . . under the arbitrary and capricious standard; legal questions under the ‘not in
accordance with law’ standard; and discretionary rulings under the abuse of discretion standard.”
Saunders v. Sec’y of Dep’t of Health & Hum. Servs., 25 F.3d 1031, 1033 (Fed. Cir. 1994)
(quoting Munn v. Sec’y of Dep’t of Health & Hum. Servs., 970 F.2d 863, 870 n.10 (Fed. Cir.
1992)).

        It is not the Court’s role “to reweigh the factual evidence, or to assess whether the special
master correctly evaluated the evidence.” Lampe v. Sec’y of Health & Hum. Servs., 219 F.3d
1357, 1360 (Fed. Cir. 2000) (quoting Munn, 970 F.2d at 871). The Court also does “not examine
the probative value of the evidence or the credibility of the witnesses. These are all matters
within the purview of the fact finder.” Id. (quoting Munn, 970 F.2d at 871). “Reversal is
appropriate only when the special master’s decision is arbitrary, capricious, an abuse of
discretion, or not in accordance with the law.” Snyder ex rel. Snyder v. Sec’y of Health & Hum.
Servs., 88 Fed. Cl. 706, 718 (2009). The arbitrary and capricious standard “is a highly
deferential standard of review[:] [i]f the special master has considered the relevant evidence of
record, drawn plausible inferences and articulated a rational basis for the decision, reversible
error will be extremely difficult to demonstrate.” Hines ex rel. Sevier v. Sec’y of Dep’t of Health
& Hum. Servs., 940 F.2d 1518, 1528 (Fed. Cir. 1991).

       B. The Standard of Causation in Vaccine Cases

         “A petitioner seeking compensation under the Vaccine Act must prove by a
preponderance of the evidence that the injury or death at issue was caused by a vaccine.”
Broekelschen v. Sec’y of Health & Hum. Servs., 618 F.3d 1339, 1341 (Fed. Cir. 2010) (citing 42
U.S.C. §§ 300aa-11(c)(1), 13(a)(1) (2018)). “A petitioner can show causation under the Vaccine
Act in one of two ways”: (1) “by showing that she sustained an injury in association with a
vaccine listed in the Vaccine Injury Table[,] . . . [i]n such a case, causation is presumed”; or (2)
“if the complained-of injury is not listed in the Vaccine Injury Table . . . the petitioner may seek
compensation by proving causation in fact.” Id. at 1341–42 (internal citations omitted). Vaccine
cases employ a burden shifting standard: “[o]nce the petitioner has demonstrated causation, she
is entitled to compensation unless the government can show by a preponderance of the evidence
that the injury is due to factors unrelated to the vaccine.” Id. at 1342 (citing Doe v. Sec’y of
Health & Hum. Servs., 601 F.3d 1349, 1351 (Fed. Cir. 2010); 42 U.S.C. § 300aa-13(a)(1)(B)).

        “When a petitioner has suffered an off-Table injury . . . [the Federal Circuit] has established
the following test for showing causation in fact under the Vaccine Act:”

       [The petitioner’s] burden is to show by preponderant evidence that the vaccination
       brought about her injury by providing: (1) a medical theory causally connecting
       the vaccination and the injury; (2) a logical sequence of cause and effect showing

                                                - 13 -
       that the vaccination was the reason for the injury; and (3) a showing of a proximate
       temporal relationship between vaccination and injury.

Broekelschen, 618 F.3d at 1345 (quoting Althen v. Sec’y of Health & Hum. Servs., 418 F.3d
1274, 1278 (Fed. Cir. 2005)). Under the first prong of Althen, “[a] petitioner must provide a
‘reputable medical or scientific explanation’ for its theory.” Boatmon v. Sec’y of Health & Hum.
Servs., 941 F.3d 1351, 1359 (Fed. Cir. 2019) (quoting Moberly ex rel. Moberly v. Sec’y of Health
& Hum. Servs., 592 F.3d 1315, 1322 (Fed. Cir. 2010)). “While it does not require medical or
scientific certainty, [the explanation] must still be ‘sound and reliable.’” Id. (quoting Knudsen ex
rel. Knudsen v. Sec’y of Dep’t of Health & Hum. Servs., 35 F.3d 543, 548–49 (Fed. Cir. 1994)).
Petitioners “need not produce medical literature or epidemiological evidence to establish
causation under the Vaccine Act.” Andreu ex rel. Andreu v. Sec’y of Dep’t of Health & Hum.
Servs., 569 F.3d 1367, 1379 (Fed. Cir. 2009). Where such evidence is introduced, it must not be
viewed “through the lens of the laboratorian, but instead from the vantage point of the Vaccine
Act’s preponderant evidence standard . . . .” Id. at 1380. For satisfying the second Althen prong,
“medical records and medical opinion testimony are favored in vaccine cases, as treating
physicians are likely to be in the best position to determine whether ‘a logical sequence of cause
and effect show[s] that the vaccination was the reason for the injury.’” Capizzano v. Sec’y of
Health & Hum. Servs., 440 F.3d 1317, 1326 (Fed. Cir. 2006) (quoting Althen, 418 F.3d at 1280).
Lastly, “the proximate temporal relationship prong requires preponderant proof that the onset of
symptoms occurred within a timeframe for which, given the medical understanding of the
disorder’s etiology, it is medically acceptable to infer causation-in-fact.” de Bazan v. Sec’y of
Health & Hum. Servs., 539 F.3d 1347, 1352 (Fed. Cir. 2008).

       C. The Standard for Issuing a Decision on the Papers Without a Hearing in Vaccine
          Cases

         The Court may “set aside any findings of fact or conclusion of law of the special master
found to be arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with
law . . . .” 42 U.S.C. § 300aa-12(e)(2)(B). This is a “highly deferential standard of review.”
Burns ex. rel. Burns v. Sec’y of Dep’t of Health & Hum. Servs., 3 F.3d 415, 416 (Fed. Cir. 1993)
(quoting Hines ex. rel. Sevier v. Sec’y of Dep’t of Health & Hum. Servs., 940 F.2d 1518, 1528
(Fed. Cir. 1991)). The Special Master’s discretionary rulings are reviewed for abuse of
discretion; such rulings “rarely come into play except where the special master excludes
evidence.” Dickerson v. Sec’y of Dep’t of Health & Hum. Servs., 35 Fed. Cl. 593, 597 (1996)
(citing Munn, 970 F.2d at 870 n.10).

       The Vaccine Act provides “a special master may conduct such hearings as may be
reasonable and necessary.” 42 U.S.C. § 300aa-12(d)(3)(B)(v) (emphasis added). A “special
master may decide a case on the basis of written submissions without conducting an evidentiary
hearing.” VRCFC 8(d); Plummer, 24 Cl. Ct. 304.

       This Court has held that a special master’s discretion to hold an evidentiary hearing is
tempered by the requirement that:

                                               - 14 -
       The special master shall be responsible for conducting all proceedings, including
       requiring such evidence as may be appropriate, in order to prepare a decision,
       including findings of fact and conclusions of law . . . [and] shall determine the
       nature of the proceedings, with the goal of making the proceedings expeditious,
       flexible, and less adversarial, while at the same time affording each party a full and
       fair opportunity to present its case . . . .

Dickerson, 35 Fed. Cl. at 598 (citing VRCFC 3(b)). Accordingly, “it is incumbent upon [a
special master] to explain to the parties the evidence which is necessary and provide them a
reasonable opportunity to come forward with it.” Id.

V. Review of the Special Master’s Decision

       A. The Special Master’s Consideration of Mr. Mager’s Proposed Causation Theory

        Mr. Mager argues the Special Master mischaracterized his argument on causation and
ignored significant points made by petitioner’s expert. Mot. for Review at 2, ECF No. 191.
Petitioner acknowledges his expert believed Ms. Mager’s epilepsy was autoimmune in nature,
but he contends “his argument for causation does not hinge [on] a diagnosis of autoimmune
epilepsy base[d] on the diagnostic criteria presented to the Court.” Id. at 16. “In fact,” petitioner
argues, “the Special Master’s reliance on that diagnostic criteria referenced in his opinion,
directly contradicts [p]etitioner’s stated reason for offering the criteria.” Id. According to
petitioner, he provided the diagnostic criteria “solely to demonstrate that autoimmune epilepsy
can present as milder epilepsy.” Id. at 16–17 (quoting Pl.’s Resp. to Special Master’s 16 June
2021 Questions at 1, ECF No. 188). Petitioner clarifies:

       In other words, [p]etitioner is not hinging his case on a diagnosis of autoimmune
       epilepsy, nor did he proffer the diagnostic criteria to support a diagnosis of autoim-
       mune epilepsy. Rather, [p]etitioner argued that [Ms. Mager] experienced SUDEP
       as a result of her epilepsy which was, yes, likely to be autoimmune in nature.

Id. Petitioner argues further the Special Master failed to address his “predominant argument,”
which he summarizes as follows:

       [Ms. Mager] experienced challenge/rechallenge, i.e.[,] that [Ms. Mager]’s
       presentation meets the classic definition of challeng[e]/rechallenge, i.e.[,]
       “rechallenge, an adverse event that occurred after more than one administration of
       a particular vaccine in the same individual.” Rechallenge is not dependent on a
       finding that [Ms. Mager] suffered from autoimmune epilepsy. It is dependent on
       [Ms. Mager] suffering an adverse event, in this case seizures, after more than one
       administration of a particular vaccine, e.g.[,] the HPV vaccination.

Id. “[T]he complexity of [Ms. Mager’s] diagnosis,” petitioner contends, “cannot be stripped
down to the three criteria as the Special Master did in this case. Particularly, when that criteria
is offered to demonstrate that autoimmune epilepsy can present in a range of severity including
the milder epilepsy from which [Ms. Mager] suffered.” Mot. for Review at 16–17. Petitioner

                                               - 15 -
concludes the Special Master abused his discretion by allegedly failing to consider the entirety of
petitioner’s case. Id. at 2, 16, 18.

        The government contended at oral argument the Special Master’s characterization of
petitioner’s argument is a factual determination subject to review under the arbitrary and
capricious standard. Tr. at 23:10–25:6. At the same time, the government recognized it is an
exercise of discretion for a special master to exclude evidence or impose limitations on the
record, and such decisions are subject to review for abuse of discretion. Tr. at 26:24–27:22
(“[GOVERNMENT]: . . . [Decisions to admit or exclude evidence] are prime examples of
exercise of judicial discretion. Limitation of the record, I construe in similar terms, in terms of
making decisions about what the Court will or will not consider . . . . And those are things that
are within the Special Master’s discretion and, therefore, there may be instances where that
discretion might be abused.”). The government also recognized it “would not necessarily be
solely a factual error” for a special master to rely on a flawed characterization of petitioner’s case
but struggled to identify the proper standard of review for such a scenario. Tr. at 30:19–31:9.

        The Court disagrees with the government’s argument that a special master’s
characterization of a petitioner’s theory of causation is a factual determination. The Federal
Circuit has held a special master’s rulings are subject to review for abuse of discretion if they
exclude evidence or limit the record on which the special master relies. Contreras v. Sec’y of
Health & Hum. Servs., 844 F.3d 1363, 1368 (Fed. Cir. 2017); Lampe v. Sec’y of Health & Hum.
Servs., 42 Fed. Cl. 632, 636 (1998) (citing Saunders, 25 F.3d at 1033). In Contreras, the Federal
Circuit found a special master abused his discretion by limiting his analysis to a single diagnosis
even though the petitioner alleged two diagnoses and the government did not dispute the nature
of the petitioner’s injury. Contreras, 844 F.3d at 1368. According to the Federal Circuit, the
special master’s decision to limit his analysis to a single diagnosis improperly limited the record
such that the special master did not consider evidence relevant to the spurned diagnosis. Id. at
1368–69. Thus, a special master’s characterization of a petitioner’s theory of causation is subject
to review for abuse of discretion. Id. at 1368 (“We review discretionary rulings—i.e., exclusion
of evidence or limitation of the record upon which the special master relies—under the abuse of
discretion standard.”) (citing Munn, 970 F.2d at 870 n.10).

        The Court may set aside a special master’s decision for abuse of discretion “if the
decision is clearly unreasonable, arbitrary, or fanciful; is based on an erroneous conclusion of
law; rests on clearly erroneous fact findings; or involves a record that contains no evidence on
which the [special master] could base its decision.” Cottingham ex. rel. K.C. v. Sec’y of Health
& Hum. Servs., 971 F.3d 1337, 1345 (Fed. Cir. 2020) (citing In re Durance, 891 F.3d 991, 1000
(Fed. Cir. 2018)).

       Petitioner’s prehearing brief summarized his argument on causation as follows:

       Petitioner’s theory of causation is a neurological autoimmune process triggered by
       the HPV vaccine, causing autoimmune epilepsy, which is strongly supported by the
       challenge/rechallenge, . . . i.e.[,] “rechallenge, an adverse event that occurred after
       more than one administration of a particular vaccine in the same individual.”
       [Ms. Mager] experienced a similar adverse event after each of two administrations

                                                - 16 -
        of her HPV vaccination. Further [Ms. Mager’s] HPV vaccination triggered an
        immune-mediated response that resulted in the development of her autoimmune
        epilepsy after her first dose, and subsequently caused the significant aggravation of
        her autoimmune epilepsy (characterized by recurrence of seizures, increased
        frequency of seizures and death from SUDEP). As it is medically most likely, the
        seizures she suffered after the first and the second HPV vaccination represent the
        same medical condition.

Pet’r’s Prehr’g Br. at 16–17, ECF No. 168 (emphasis added). Notably, petitioner’s prehearing
arguments mention three times that the HPV vaccine resulted in autoimmune epilepsy.
Petitioner agrees Ms. Mager’s condition does not satisfy the diagnostic criteria for autoimmune
epilepsy, Tr. at 34:7–20, but he argues Ms. Mager’s condition was a milder form of generalized
epilepsy that was autoimmune in nature and caused by an autoimmune reaction. Tr. at 52:14–
53:2. In other words, petitioner argues Ms. Mager’s condition is not Autoimmune Epilepsy—
“capital A, capital E”—as defined by the diagnostic criteria but epilepsy that is autoimmune in
nature. Tr. at 108:15–109:9. The parties agreed arguendo considering petitioner’s distinction
this way—i.e., Autoimmune Epilepsy being defined by the diagnostic criteria and autoimmune
epilepsy being epilepsy that is autoimmune in nature—assists with discussion. Tr. at 108:19–
110:8 (“THE COURT: . . . If there is a distinction between Autoimmune Epilepsy, capital A,
capital E [,] . . . and just autoimmune epilepsy, lowercase—[GOVERNMENT]: Got it.”).

       To support his argument, petitioner pointed to “the direct relationship with the HPV
vaccination strongly supported by the challenge/rechallenge circumstances.” Pet’r’s Prehr’g Br.
at 9. He also referred to “[a]dditional supporting evidence” of inflammation of the brain, which
was detailed in the postmortem report. Id.

        Petitioner further argued the medical literature demonstrates autoimmune epilepsy can be
difficult to distinguish from other types of epilepsy. For example, petitioner referred to an
Australian study involving 114 patients with new onset seizures, 11 of which tested positive for
one or more autoantibodies compared to three of 65 control patients. Id. at 39–40 (citing Pet’r’s
Ex. 88, ECF No. 165-5). Petitioner summarized disparate data characterizing patients with and
without autoantibodies and suggested this data demonstrates autoimmune epilepsy presents in
various ways and can be difficult to identify. Id. at 40. Petitioner explained:

        Overall, there was no significant difference in the demographic or clinical pictures
        between the antibody positive and the antibody negative group. . . . The article
        does not prove that the antibodies were the cause of the epilepsy, but it is a very
        solid possibility . . . . Overall, [the article] shows that neuronal antibodies are
        relatively common in patients with new onset epilepsy, which is otherwise
        considered idiopathic and that the epileptic presentation is very variable.

Id. at 40–41. In other words, autoimmune epilepsy can be difficult to distinguish from other
types of epilepsies. 4 This study, petitioner argued, also demonstrates autoimmune epilepsy can

4
 While petitioner speaks of neuronal antibodies as an indicator of autoimmune epilepsy, Ms. Mager’s blood was
never tested for neuronal antibodies. The Special Master recognized petitioner’s “potentially valid reasons” why

                                                      - 17 -
present in milder epilepsy cases. Id. at 9–10. Petitioner referred to this study, along with the
diagnostic criteria for autoimmune epilepsy, to support the proposition that autoimmune epilepsy
can present as milder epilepsy. Pet’r’s Prehr’g Br. at 9–10. Petitioner held this position
consistently throughout the prehearing proceedings. 5

         Before making his decision on compensation, the Special Master followed up with
petitioner asking him to “identify the source of the diagnostic criteria for autoimmune epilepsy
listed in his [prehearing] brief.” Order at 1, ECF No. 187. Petitioner responded accordingly but
noted “[t]he criteria are discussed in that section solely to demonstrate that autoimmune epilepsy
can present as milder epilepsy.” Pl.’s Resp. to Special Master’s 16 June 2021 Questions at 1.

        In his decision denying compensation, the Special Master acknowledged and quoted
petitioner’s language identifying the source of his diagnostic criteria, Decision Den.
Compensation at 4 n.3, ECF No. 189, but omitted petitioner’s clarification that “[t]he criteria are
discussed solely to demonstrate that autoimmune epilepsy can present as milder epilepsy,” Pl.’s
Resp. to Special Master’s 16 June 2021 Questions at 1 (emphasis added). The Special Master
then proceeded to apply the diagnostic criteria to the evidence in the record despite petitioner’s
clarification, ultimately concluding there was insufficient evidence to support a diagnosis of
Autoimmune Epilepsy and denying petitioner’s claim on that basis. Id. at 16–17.

        The exchange between the Special Master and petitioner clarifying the source and
purpose of the diagnostic criteria demonstrates two important points: (1) petitioner was not
arguing a diagnosis of Autoimmune Epilepsy was necessary; and (2) there was a
misunderstanding between petitioner and the Special Master concerning the relevance of the
diagnostic criteria for autoimmune epilepsy. Counsel for the government—who also
acknowledges misunderstanding the argument—recognizes the Special Master may have
misunderstood petitioner’s argument. Tr. at 61:22–25 (“COURT: So is it possible the Special
Master misunderstood [p]etitioner’s argument? [GOVERNMENT]: I certainly did, so certainly
that’s possible.”). Petitioner’s clarification apparently did not clear up that misunderstanding
since the Special Master proceeded to apply the diagnostic criteria as if it were central to his
argument. 6 See Decision Den. Compensation.

         While the Special Master’s analysis of the diagnostic criteria was careful and thorough, it
was also not necessary—petitioner agrees Ms. Mager’s condition does not fit the diagnostic
criteria neatly. Tr. at 34:7–20 (“I do not believe that she meets the diagnostic criteria. Neither
does Dr. Shafrir . . . . We’ve not alleged that she meets that diagnostic criteria in this case.”).
Petitioner argues the diagnostic criteria are a starting point but there is no requirement that they
be firmly adhered to. Tr. at 37:12–38:3 (“The diagnostic criteria . . . [are] the point where you

Ms. Mager’s doctors did not test her blood for neuronal antibodies, such as the emerging nature of the diagnosis.
Decision Den. Compensation at 10.
5
 As discussed below, petitioner maintained this position when asked to identify the source of his diagnostic criteria.
He responded: “[t]he criteria are discussed in that section solely to demonstrate that autoimmune epilepsy can
present as milder epilepsy.” Pl.’s Resp. to Special Master’s 16 June 2021 Questions at 1, ECF No. 188.

6
 The Special Master’s apparent misunderstanding of petitioner’s argument likely could have been clarified if a
hearing had been held.

                                                        - 18 -
start. . . . And the diagnostic criteria [are] typically based on developing treatment modalities
and things like that. In a clinical setting, doctors use diagnostic criteria, but they’re not married
to them. . . . [Y]ou get people diagnosed all the time [who] don’t meet diagnostic criteria.”).

        The Vaccine Act jettisons strict adherence to diagnostic criteria for a more flexible
approach to proving causality. Knudsen ex rel. Knudsen v. Sec’y of Dep’t of Health & Hum.
Servs., 35 F.3d 543, 548–49 (Fed. Cir. 1994) (“Causation in fact under the Vaccine Act is thus
based on the circumstances of the particular case, having no hard and fast per se scientific or
medical rules. The determination of causation in fact under the Vaccine Act involves
ascertaining whether a sequence of cause and effect is ‘logical’ and legally probable, not
medically or scientifically certain.”) (citing Bunting v. Sec’y of Dep’t of Health & Hum. Servs.,
931 F.2d 867, 873 (Fed. Cir. 1991)); Andreu ex rel. Andreu v. Sec’y of Dep’t of Health & Hum.
Servs., 569 F.3d 1367, 1382 (Fed. Cir. 2009) (“[T]he function of a special master is not to
‘diagnose’ vaccine-related injuries, but instead to determine ‘based on the record evidence as a
whole and the totality of the case, whether it has been shown by a preponderance of the evidence
that a vaccine caused the child’s injury.’” (quoting Knudsen, 35 F.3d at 549)).

          In providing a thorough analysis of the diagnostic criteria, the Special Master missed the
core of petitioner’s argument—the vaccine caused an autoimmune response triggering recurrence
and aggravation of Ms. Mager’s epilepsy disorder. Tr. at 63:10–14. Petitioner devoted several
pages of arguments in support of his theory that the HPV vaccine triggered recurrence and
aggravation of Ms. Mager’s seizure disorder, see Pet’r’s Prehr’g Br. at 14–17; these arguments
were unaddressed in the Special Master’s decision, Tr. 75:10–76:2 (“COURT: So explain that
out more. That there was not proper weight given to challenge/rechallenge. [PETITIONER]:
. . . I don’t think [the Special Master] did any analysis [in] that regard. . . . COURT: Does the
[g]overnment have anything on that? [GOVERNMENT]: I don’t believe he did.”).

        By focusing his analysis on the diagnostic criteria for Autoimmune Epilepsy—criteria the
petitioner provided only to demonstrate the breadth of severity with which autoimmune epilepsy
can manifest—the Special Master did not consider petitioner’s primary argument; i.e., an
autoimmune reaction to the HPV vaccine triggered recurrence and aggravation of Ms. Mager’s
epilepsy disorder. The Special Master is statutorily mandated to consider all relevant medical
and scientific evidence contained in the record, 42 U.S.C. § 300aa-13(b)(1); the Court therefore
must find this constitutes an abuse of discretion, Contreras, 844 F.3d at 1368–69 (finding a
special master committed reversible error by failing to consider relevant evidence related to the
petitioner’s medical theories).

       B. The Special Master’s Legal Requirement, if any, to Analyze the Case Under
          Althen and its Progeny

        The parties in this case agree Ms. Mager suffered from an epileptic seizure disorder, but
they dispute the underlying diagnosis of the disorder—petitioner argues autoimmune epilepsy
while the government argues JME. Decision Den. Compensation at 4. In view of these
competing diagnoses, the Special Master, citing Lombardi and Broekelschen, set out as a
threshold matter to determine which diagnosis was correct. The Special Master found petitioner
did not meet his burden to show by preponderant evidence Ms. Mager suffered from

                                                - 19 -
Autoimmune Epilepsy. Id. at 16–17. The Special Master considered a diagnosis of
Autoimmune Epilepsy to be necessary for petitioner to succeed, so he denied the petition without
analyzing whether the vaccine caused or aggravated Ms. Mager’s epilepsy disorder under Althen.
Id. The Court reviews de novo the Special Master’s decision to diagnose Ms. Mager’s condition
and dismiss the case without analyzing whether the HPV vaccine caused Ms. Mager’s injury
under Althen. Broekelschen, 618 F.3d at 1345 (holding the Court “owe[s] no deference to the . . .
special master on questions of law.”).

         For off-Table vaccine cases, the petitioner bears the burden of showing she “sustained, or
had significantly aggravated, any illness, disability, injury, or condition not set forth in the
Vaccine Injury Table . . . .” 42 U.S.C. § 300aa-11(c)(1)(C)(ii)(I). “[T]he statute places the
burden on the petitioner to make a showing of at least one defined and recognized injury . . . not
merely a symptom or manifestation of an unknown injury.” Lombardi v. Sec’y of Health &
Hum. Servs., 656 F.3d 1343, 1353 (Fed. Cir. 2011). The Vaccine Act provides compensation for
“any illness, disability, injury, or condition not set forth in the Vaccine Injury Table . . . which
was caused by a [designated] vaccine . . . .” 42 U.S.C. § 300aa-11(c)(1)(C)(ii)(I) (emphasis
added). A petitioner need not diagnose her injury, she must merely “show that the vaccine in
question caused [her] injury—regardless of the ultimate diagnosis.” Kelley v. Sec’y of Health &
Hum. Servs., 68 Fed. Cl. 84, 100 (2005) (citing 42 U.S.C. § 300aa-11(c)(1)(C)(ii)(I)). If,
however, “the existence and nature of the injury itself is in dispute, it is the special master’s duty
to first determine which injury was best supported by the evidence presented in the record before
applying the Althen test to determine causation of that injury.” Lombardi, 656 F.3d at 1352
(citing Broekelschen, 618 F.3d at 1346). Absent a “showing of the very existence of any specific
injury of which the petitioner complains, the question of causation is not reached.” Lombardi,
656 F.3d at 1353.

        In this case, petitioner alleges the HPV vaccine caused or aggravated Ms. Mager’s
epileptic seizure disorder ultimately resulting in her death. Am. Pet. at 2, ECF No. 11; Mot. for
Review at 10. Petitioner submitted evidence showing Ms. Mager indeed suffered from an
epileptic seizure disorder that caused her death. The government does not dispute this. Tr. at
95:8–11. Instead, the government contends Ms. Mager’s injury could not have been caused by
the vaccine because her underlying diagnosis is better diagnosed as JME. The government’s
argument fails, however, because JME and autoimmune epilepsy are variants of the same
disorder—i.e., a seizure disorder. Gov’t’s Prehr’g Br. at 14, ECF No. 180 (arguing Ms. Mager
suffered from a generalized seizure disorder); Gov’t’s Ex. BB at 12, ECF No. 183-1 (explaining
Ms. Mager was diagnosed with a primary generalized epilepsy disorder); Tr. at 95:8–11
(“COURT: . . . The Government does not disagree that [Ms. Mager] suffered from a seizure
disorder. [GOVERNMENT]: No.”); Tr. at 93:12–15 (“[PETITIONER]: I mean, they’re both
epilepsy and they’re both seizure disorders.”).

        While this case involves competing diagnoses, they are only competing in the sense that
the parties dispute them—not in the sense that they are mutually exclusive. Tr. at 85:23–25
(“[GOVERNMENT]: Do I think there’s anything that would preclude her from having an
autoimmune response, no.”). While autoimmune epilepsy is characterized in terms of its
etiology, or causality, Tr. at 7:14–20, 40:19–22, JME is characterized in terms of its phenotype,
or observable characteristics, see Gov’t’s Ex. BB at 2. Unlike the competing diagnoses in

                                                - 20 -
Broekelschen and Lombardi, juvenile myoclonic epilepsy is an idiopathic generalized epilepsy
disorder—its cause is unknown. Gov’t’s Ex. BB at 2. The question of causation cannot turn on
a diagnosis if its underlying cause is unknown, particularly when the disputed diagnoses are
variants of the same disorder as they are here. Broekelschen, 618 F.3d at 1346, 1349 (holding
where “the injury itself is in dispute, the proposed injuries differ significantly in their pathology,
and the question of causation turns on [the] injury” it is appropriate for the special master to first
determine which injury the evidence supports).

        The outcome in Lombardi is also distinguishable from the outcome in this case because
Lombardi was “unusual in that the identification of the injury and its nature [were] in dispute.”
Lombardi, 656 F.3d at 1352. In contrast, there is no dispute in this case that Ms. Mager suffered
from an epileptic seizure disorder that resulted in her death. Tr. at 95:8–11. Moreover, in
addition to extreme disagreement between experts, 7 the Federal Circuit noted the competing
conditions in Lombardi were not “so similar that doctors consider them to be conditions along a
spectrum of diseases.” Lombardi, 656 F.3d at 1352. By contrast, both competing diagnoses
here are variants which fit within the category of epileptic seizure disorders. Tr. at 9:2–3; 12:4–
5. Moreover, the government admits Lombardi is factually distinguishable from this case. Tr. at
91:5–8.

        This case is distinguishable from Broekelschen for the same reasons, but also because the
parties agree Ms. Mager suffered from a seizure disorder—a fact that distinguished Broekelschen
from the Federal Circuit’s precedents. Broekelschen, 618 F.3d at 1346 (distinguishing
Broekelschen from Andreu because “the parties agreed that the petitioner suffered from a seizure
disorder”). Further, the competing diagnoses in Broekelschen are unlike the two competing
diagnoses in this case, which are both epileptic in nature and variants of the same disorder. Cf.
Broekelschen, 618 F.3d at 1346.

         The Special Master’s inquiry into the underlying diagnosis of Ms. Mager’s seizure
disorder places too much emphasis on the diagnostic criteria for autoimmune epilepsy and too
little on whether she suffered an injury. See, e.g., Decision Den. Compensation at 4 (“The
difference between autoimmune epilepsy and JME affects the outcome of [petitioner’s] case
because his theory of causation relies on an autoimmune disease causing neuroinflammation.”).
The inquiry improperly narrows the analysis on diagnostic criteria the petitioner never alleged it
satisfied. By narrowly focusing on the diagnostic criteria, the Special Master denied the
petitioner’s claims on grounds the petitioner never argued in making his case. Tr. 29:9–30:9
(“And in doing that, it essentially set up a strawman argument that could be knocked down. You
know, we can’t defend a diagnosis that we didn’t allege.”). In doing so, the Special Master
effectively abbreviated the causation analysis, which is an improper application of the Federal
Circuit’s holding in Broekelschen. W.C. v. Sec’y of Health & Hum. Servs., 704 F.3d 1352, 1357

7
  The petitioner in Lombardi alleged she suffered from three different medical conditions: transverse myelitis,
chronic fatigue syndrome, and systemic lupus erythematosus. Lombardi, 656 F.3d at 1351. The government’s
experts, on the other hand, refuted the petitioner’s proposed medical conditions and proposed five others. Id. at
1352–53. Further complicating matters, the government’s expert witness testimony “refuted each of those diagnoses
and proposed five other possible conditions that Lombardi may have suffered from.” Id. “In the face of such
extreme disagreement among well-qualified medical experts,” the Federal Circuit reasoned, “it was appropriate for
the special master to first determine what injury, if any, was supported by the evidence presented in the record
before applying the Althen test to determine causation.” Id. at 1352–53.

                                                     - 21 -
(Fed. Cir. 2013) (explaining where parties agreed on injury and “the issue [was] whether the
vaccine caused [p]etitioner’s [injury], the special master should have expressly applied the
analysis set forth in Althen”); Lombardi, 656 F.3d at 1358 (O’Malley, J., concurring) (expressing
concern with “provid[ing] a mechanism for special masters to shortcut the causation analysis in
instances where the alleged injuries can support multiple diagnoses”); see also Broekelschen,
618 F.3d at 1352 (Mayer, J., dissenting on other grounds) (“[The] approach, of first assigning a
diagnosis to [petitioner’s] symptoms before applying the Althen test, is not supported by statute,
caselaw, or logic, and its effect [is] to impermissibly heighten [petitioner’s] burden.”).

         The “existence and nature of the injury” was not in dispute, so the Special Master erred in
failing to consider whether the vaccine caused Ms. Mager’s injury under Althen and its progeny.
W.C., 704 F.3d at 1357 (finding the special master improperly failed to carry out analysis under
Althen where parties agreed on petitioner’s injury); Contreras, 844 F.3d at 1368–69 (finding the
special master erred by inquiring into petitioner’s diagnosis and failing to conduct a complete
Althen analysis for all medical disorders alleged by the petitioner). For these reasons, the Court
finds the Special Master must perform the requisite causation analysis under Althen and its
progeny. W.C., 704 F.3d at 1357 (finding where parties agreed on injury and “the issue [was]
whether the vaccine caused [p]etitioner’s [injury], the special master should have expressly
applied the analysis set forth in Althen”); Contreras, 844 F.3d at 1368 (finding the special master
erred in conducting a threshold inquiry into the specific diagnosis of the alleged vaccine injury).

VI. Whether the Special Master is Obliged to Consider the Entire Record in View of his
    Decision to not Hold an Evidentiary Hearing

        In deciding the case on the papers without an evidentiary hearing, the Special Master
reasoned “[a] hearing to determine the threshold issue of diagnosis in this case is not needed.
The parties have had ample opportunity to develop their positions through submissions of
evidence (primarily medical records) about [Ms. Mager], lengthy and multiple expert reports,
and thorough briefing.” Decision Den. Compensation at 18. Petitioner argues, under Moriarty,
the Special Master’s decision to forgo an evidentiary hearing in this case requires the Special
Master to consider the entire record. Mot. for Review at 15–16. Petitioner acknowledges the
Special Master is not required to conduct an evidentiary hearing but contends “[i]f a [s]pecial
[m]aster may not, as a matter of law, decline to consider evidence on the record only because it
was not discussed at [a] hearing it is even more imperative that he consider all the evidence when
he also declines to conduct a hearing.” Id. The Court reviews discretionary rulings, such as
exclusion of evidence or limitation of the record, upon which the Special Master relies under the
abuse of discretion standard. Contreras, 844 F.3d at 1368.

        The Vaccine Rules authorize a special master to make findings of fact and decide a case
based on the written record without an evidentiary hearing. See VRCFC 8(d); Plummer v. Sec’y
of Dep’t of Health & Hum. Servs., 24 Cl. Ct. 304, 307 (1991). Whether to hold a hearing is a
matter within a special master’s discretion. 42 U.S.C. § 300aa-12(d)(3)(B)(v) (a special master
“may conduct such hearings as may be reasonable and necessary”) (emphasis added). The
Vaccine Act requires a special master to consider any medical records or reports “contained in
the record regarding the nature, causation, and aggravation of the petitioner’s . . . injury” as well
as “all other relevant medical and scientific evidence contained in the record.” 42 U.S.C.

                                                - 22 -
§ 300aa-13(b). The statute also requires special masters to “‘consider the entire record and the
course of the injury’ when evaluating the weight to be afforded to any medical records or reports
present in the record.” Moriarty by Moriarty v. Sec’y of Health & Hum. Servs., 844 F.3d 1322,
1327 (Fed. Cir. 2016) (quoting 42 U.S.C. § 300aa-13(b)). Accordingly, a special master must
consider any relevant medical records or reports contained in the entire record of the case. Id.
Unless the Special Master expressly indicates he did not consider certain evidence, a
presumption applies that he “considered the relevant record evidence even though he does not
explicitly reference such evidence in his decision.” Id. at 1328.

        The inquiry in this case is straightforward. The Court starts from the presumption that “a
special master considered the relevant record evidence even though he does not explicitly
reference such evidence in his decision.” Id. In this case, the Special Master did not expressly
indicate he did not consider certain relevant evidence. See Decision Den. Compensation.
Petitioner admits there is no indication in this case the Special Master failed to consider evidence
relevant to a diagnosis of autoimmune epilepsy. Tr. at 35:10–23. In the absence of any
indication the Special Master failed to consider any relevant evidence for a diagnosis of
autoimmune epilepsy, the presumption maintains.

        Petitioner is correct that a special master is required to consider the entire record of the
case, 42 U.S.C. § 300aa-13(b), but petitioner has not shown that the Special Master failed to
consider any relevant evidence. Moreover, petitioner neglects the Federal Circuit’s emphasis on
relevant evidence, Moriarty, 844 F.3d at 1327–28 (“[A] special master . . . must consider all
relevant medical and scientific evidence . . . , which includes any relevant medical records or
reports. . . . [T]he special master ‘shall’ consider the entire record, which includes this relevant
evidence . . . .”). A special master’s burden to consider evidence contained within the record
extends only to evidence relevant to the factual inquiry at hand. Moriarty, 844 F.3d at 1327–28;
42 U.S.C. § 300aa-13(b). The Federal Circuit in Moriarty found the special master in that case
erred by failing to consider relevant expert testimony. Moriarty, 844 F.3d at 1328. There is no
indication here that the Special Master did not consider evidence relevant to Ms. Mager’s
diagnosis.

        To the extent the Special Master was required to consider all evidence relevant to making
a factual finding on Ms. Mager’s diagnosis, the Court finds the Special Master did not err. Id.
As discussed above, however, the Special Master improperly viewed the evidence through the
narrow lens of diagnostic criteria rather than petitioner’s actual theory and failed to carry out a
causation analysis under Althen and its progeny. The Court makes no finding regarding whether
the Special Master considered all relevant evidence to that inquiry.

VII. Conclusion

       For the above reasons, petitioner’s motion for review is GRANTED and the Special
Master’s 29 July 2021 Decision Denying Compensation, ECF No. 189, is VACATED. The case
is REMANDED for the Special Master to determine whether petitioner can satisfy the required

                                               - 23 -
elements for an off-Table claim under Althen and its progeny, and for other proceedings
consistent with this Opinion.

       IT IS SO ORDERED.

                                                      s/ Ryan T. Holte
                                                      RYAN T. HOLTE
                                                      Judge

                                             - 24 -